263162-13-6

Basic information

• Product Name: Carbamic acid, [2-[(2-aminoethyl)methylamino]ethyl]-, 1,1-dimethylethyl ester
• Synonyms: Carbamic acid, [2-[(2-aminoethyl)methylamino]ethyl]-, 1,1-dimethylethyl ester;{2-[(2-AMino-ethyl)-Methyl-aMino]-ethyl}-carbaMic acid tert-butyl ester;tert-Butyl (2-((2-aMinoethyl)(Methyl)aMino)ethyl)carbaMate
• CAS NO: 263162-13-6
• Molecular Formula: C₁₀H₂₃N₃O₂
• Molecular Weight: 217.30852
• Product Categories: N-BOC
• Mol File: 263162-13-6.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 309.8±22.0 °C(Predicted)
• Appearance: /
• Density: 1.001±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.98±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [2-[(2-aminoethyl)methylamino]ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-[(2-aminoethyl)methylamino]ethyl]-, 1,1-dimethylethyl ester(263162-13-6)
• EPA Substance Registry System: Carbamic acid, [2-[(2-aminoethyl)methylamino]ethyl]-, 1,1-dimethylethyl ester(263162-13-6)

Safety Data

• Hazardous Substances Data: 263162-13-6(Hazardous Substances Data)

Usage

General Description

Carbamic acid, [2-[(2-aminoethyl)methylamino]ethyl]-, 1,1-dimethylethyl ester, also known as terbutaline, is a chemical compound used primarily as a bronchodilator to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. It works by relaxing the smooth muscles in the airways, making it easier to breathe. Terbutaline is also used to prevent premature labor by relaxing the uterine muscles. It is commonly administered through inhalation or oral tablets. However, it should be used with caution and under the guidance of a healthcare professional due to potential side effects and interactions with other medications.

Upstream product

• 4097-88-5 1,5-diamino-3-azamethylpentane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 34619-03-9 tert-butyldicarbonate 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 

Downstream Products

• 856909-79-0 C₃₆H₅₆N₆O₆Se₂ 
• 1235236-46-0 tert-butyl 2-((2-(2-hydroxybenzamido)ethyl)(methyl)amino)ethylcarbamate 
• 1286174-12-6 N-(2-((2-aminoethyl)(methyl)amino)ethyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide hydrochloride 
• 1286174-07-9 (4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-((2-(2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamido)ethyl)(methyl)amino)ethyl)docosa-4,7,10,13,16,19-hexaenamide 
• 1286174-09-1 tert-butyl 2-((2-(2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamido)ethyl)(methyl)amino)ethylcarbamate 
• 1235236-10-8 N-(2-((2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)(methyl)amino)ethyl)-2-hydroxybenzamide 
• 1384352-91-3 C₃₅H₄₈N₄O₆ 
• 1859141-26-6 1-((2-((2-((7-chloroquinolin-4-yl)amino)ethyl)(methyl)amino)ethyl)amino)-4-methyl-9H-thioxanthen-9-one 

Relevant articles and documents

DNA-Targeted 1,2,4-Benzotriazine 1,4-Dioxides: Potent Analogues of the Hypoxia-Selective Cytotoxin Tirapazamine

Tirapazamine (TPZ, 1,2,4-benzotriazin-3-amine 1,4-dioxide) is a bioreductive hypoxia-selective cytotoxin, currently in phase II/III clinical trials in combination with radiotherapy and with cisplatin-based chemotherapy. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ where a DNA-targeting chromophore is attached at the 3-position via a flexible linker. DNA binding affinity was modified through variation of the chromophore or the pKa of the linker chain. The association constants (K DNA) for calf thymus DNA ranged from 1 × 102 to 5.6 × 105 M-1 (ionic strength of 0.01 M). DNA binding affinity was dependent on the presence of a positive charge, either in the linker chain or in the chromophore, and (for a series of 4-acridine carboxamide chromophore analogues) correlated strongly with linker chain pKa. The efficacy of these BTOs in killing aerobic and hypoxic mouse SCCVII tumor cells in vitro was determined by clonogenic survival. Cytotoxicity was measured as the concentration required to reduce plating efficiency to 10% of controls (C10), and the hypoxic cytotoxicity ratio (HCR) for each BTO was calculated as C10(aerobic)/C10(hypoxic). BTOs bearing a positive charge showed increased hypoxic cytotoxicity (1.5-56-fold) compared to TPZ and mostly modest HCRs (8-51), but some excellent (a strong correlation between KDNA and hypoxic cytotoxicity but no correlation between KDNA and HCR. Cytotoxicity in HT-29 human colon carcinoma cells, determined using IC50 assays, showed similar relationships with a correlation between KDNA and hypoxic cytotoxicity but no correlation between KDNA and HCR. In this cell line, a higher proportion of compounds (7 of 11) had HCRs greater than or equal to that of TPZ. The data confirm that DNA targeting is a useful concept for increasing potency while maintaining hypoxic selectivity and provide a direction for the further development of DNA-targeted analogues of TPZ.

A Universal Labeling Strategy for Nucleic Acids in Expansion Microscopy

Expansion microscopy (ExM) enables the nanoscale imaging of ribonucleic acids (RNAs) on a conventional fluorescence microscope, providing information on the intricate patterns of gene expression at (sub)cellular resolution and within spatial context. To extend the use of such strategies, we examined a series of multivalent reagents that allow the labeling and grafting of deoxyribonucleic acid (DNA) oligonucleotide probes in a unified approach. We show that the reagents are directly compatible with third-generation in situ hybridization chain reaction RNA FISH (fluorescence in situ hybridization) techniques while displaying complete retention of the targeted transcripts. Furthermore, we validate and demonstrate that our labeling method is compatible with multicolor staining. Through oligonucleotide-conjugated antibodies, we demonstrate excellent performance in ×4 ExM and ×10 ExM, achieving a resolution of ～50 nm in ×10 ExM for both pre- and postexpansion labeling strategies. Our results indicate that our multivalent molecules enable the rapid functionalization of DNA oligonucleotides for ExM.

SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline or thioxanthenone (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious diseases, conditions and symptoms caused by a viral infection (e.g., COVID-19)).